Press Releases WPD Pharmaceuticals Inc.

Equities

WBIO

CA92941F1053

Delayed Canadian Securities Exchange Other stock markets 14:49:31 28/06/2022 BST			5-day change	1st Jan Change
0.045 ^CAD	-.--%		-.--%	-.--%

02-05	WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
02-02	WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

WPD Pharmaceuticals : Sp. z o. o., received the second tranche of the funds	11-02	PU
WPD Pharmaceuticals : Sp. z o. o., received the first tranche of the funds	08/09/23	PU
WPD Pharmaceuticals : Polish Subsidiary Signs Investment Agreement with ACRX Investments Limited	01/09/23	PU
WPD Pharmaceuticals : Announces Closing of Convertible Debenture Private Placement	16/06/23	PU
WPD Pharmaceuticals : Provides a Corporate Update	18/11/22	PU
IIROC Trading Halt - WBIO	11/07/22	AQ
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences	16/05/22	GL
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences	16/05/22	AQ
WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project	07/03/22	GL
WPD Pharmaceuticals Announces Proposed Restructuring of Polish Subsidiary	09/02/22	GL
WPD Pharmaceuticals Announces Appointment of New Director	03/02/22	AQ
WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity	01/02/22	AQ
WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech	25/01/22	GL
WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech	25/01/22	GL
WPD Pharmaceuticals Signs Agreement with NCRD for $6.3M Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML	16/12/21	GL
WPD Pharmaceuticals : Announces AGSM Results	04/10/21	AQ
WPD Pharmaceuticals : Announces AGSM Results	01/10/21	GL
WPD Pharmaceuticals Announces AGM September 29; Plans Different Path to Fundraising Through Delisting; WPD Poland Arranges Additional Loans; Communications Consultant in Poland	02/09/21	GL
WPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans	12/07/21	GL
WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in 2H 2021	28/06/21	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases WPD Pharmaceuticals Inc.

Equities

WBIO

CA92941F1053

Press Releases

Filters